# A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

> **NCT04804059** · PHASE1 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 10 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** [14C]-APX001 Oral Solution
- **DRUG:** [14C]-APX001 Solution for Infusion

## Key facts

- **NCT ID:** NCT04804059
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-17
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-09-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04804059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04804059, "A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04804059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*